Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ImmuneRegen’s Homspera stimulates adult stem cell activity
The results show Homspera to be effective in stimulating human, adult, blood-forming stem cells (hematopoietic stem cells), which have previously been shown to be capable of becoming blood
The results show Homspera to be effective in stimulating human, adult, blood-forming stem cells (hematopoietic stem cells), which have previously been shown to be capable of becoming blood
Laboratory Corporation of America Holdings’s (LabCorp’s) Esoterix Clinical Trials Services Division was also selected by OncoMethylome as one of its preferred sub-contractors of MGMT methylation testing services for
The interim analysis showed that dosing of VX-770, an investigational CF potentiator, as an oral agent for 14 days resulted in improved lung function and in improved function
The manufacturing work is planned to conclude in the third quarter of 2008. Protexia is being developed by PharmAthene as a pre- and post-exposure therapy for victims of
Volunteers received oral doses of 250mg, 400mg or 800mg of ST-246 once a day for 21 days. The Phase I clinical trial was performed at the Orlando Clinical
At the effective time of the merger, each MediVision ordinary share will be converted into 1.66 shares of Ophthalmic Imaging Systems (OIS) common stock, for a total of
MethylGene will be responsible for the design, synthesis, characterization and initial screening of kinase inhibitors. Otsuka will be responsible for and fund efficacy and toxicology studies, as well
At closing, Avanir will issue an aggregate of approximately 35 million shares at a price of $1.14 per share unit with 35% warrant coverage. The warrants, which represent
The multinational Phase III clinical trial enrolled over 1,000 men and their female partners from 22 countries to measure improvement of sexual functioning while taking 30mg or 60mg
Aida’s subsidiary, Hanzhou Aida Pharmaceuticals, has acquired 43% of the institute from Jinou Medicine, while another of Aida’s subsidiaries, Changzhou Fangyuan Pharmaceutical, has acquired an additional 55% from